Navigation Links
New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
Date:10/31/2008

- Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study

of Liver Diseases -

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that new Nexavar data will be presented at the upcoming 59th Annual Meeting of the American Association for the Study of Live Diseases (AASLD) demonstrating the clinical application of Nexavar(R) (sorafenib) tablets in multiple patient subsets with hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the only systemic treatment to demonstrate prolonged overall survival in unresectable HCC and is currently approved in more than 60 countries for the treatment of the disease.

Data will be presented evaluating specific patient subpopulations from the Phase 3 SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific trials. The trials enrolled 602 and 226 patients, respectively, with advanced, unresectable HCC who had not received prior systemic therapy. Patients in both studies were randomized to receive either Nexavar 400 mg twice daily or placebo. Data from both Phase 3 trials demonstrated that patients treated with Nexavar experienced a significant improvement in overall survival; 44% (HR=0.69; p-value=0.0006) in the SHARP trial and 47% (HR=0.68; p-value=0.014) in the Asia Pacific trial.

"The SHARP and Asia Pacific trials continue to increase our understanding and provide clinical confirmation of the efficacy, safety and clinical benefit of Nexavar in patients with liver cancer," said Mark Gelder, MD, vice president, Therapeutic Area Oncology
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
2. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
7. Actavis Confirms its Patent Challenge of Kings Avinza(R)
8. Barr Confirms Patent Challenge of UROXATRAL(R)
9. Pennsylvania Game Commission Announces EHD Confirmed in Allegheny and Westmoreland Counties
10. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
11. Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... New York (PRWEB) March 01, 2015 ... hip lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go ... defense must prepare a witness to provide testimony ... in the development of the Profemur device, Bernstein ... in U.S. District Court, Northern District of Iowa ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured ... takes a look at the latest and coolest technology products ... NewsWatch and a technology expert, conducted the review and shared ... drinks. , According to Home Distillation of Alcohol, it's understood ... there’s a pretty cool product that’ll help anyone achieve a ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... antioxidants may protect people like athletes, soldiers from fatal temperature ... key to curing heat stroke may have been found in ... suffer a deadly rise in body temperature, according to a ... April 4 issue of Cell , also suggest that ...
... Patients with genital and nipple piercings, also known as ... positive discussions about them, according to a new article in ... too often, such discussions do not occur, even when treating ... healthcare providers uneasiness over this increasingly common form of body ...
... Care Net,President Melinda Delahoyde spoke out Thursday about the ... that,these two young girls felt that secretly disposing of ... Delahoyde. "We are saddened they,didn,t receive help from one ... Houston to offer hope and assistance to people like ...
... a Convenient Chewable ... Tablet, ... weather also brings the onslaught of insects and,parasites, including fleas. For many ... oral flea protection product from,Eli Lilly and Company, protecting your dog from ...
... health care information to,patients for disease management, case ... Today URAC called,for public comment on revisions to ... programs. URAC is seeking input from any,interested parties, ... and health plans. The deadline for public,comment is ...
... Caves reveal genetic material in excrement linking New World ... News) -- The oldest human DNA ever found in ... or East Asia, according to an international team of ... on maternally) was discovered in 14,300-year-old dried human excrement, ...
Cached Medicine News:Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 2Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 3Health News:Tragedies Point to Need for Pregnancy Centers, Care Net Says 2Health News:Spring Weather Brings Flea Season 2Health News:Spring Weather Brings Flea Season 3Health News:URAC Releases Draft Standards for Public Input for Nine Health Care Management Accreditation Programs 2Health News:DNA Find in Oregon Is Oldest Yet Discovered in Americas 2
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... OF PRUSSIA, Pa. , Feb. 27, 2015 /PRNewswire/ ... of its ongoing commitment to the global bleeding disorders ... is donating 2 million international units (IUs) of protein ... is an international not-for- profit organization which has worked ... other inherited bleeding disorders. The donation supports the WFH,s ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
Test for prostatic acid phosphatase...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
... a Windows 2000 PC based EEG with ... and software. EEG-9200 provides high quality performance ... in the sleep lab or EEG lab. ... the electrically noisy OR or ICU. Neurofax ...
... the first magnetic stimulator to offer the ... It is designed to provide the simplest ... routine (at the same time, it may ... can control operations without moving away from ...
Medicine Products: